Lack of chips produces “no negative effects on print quality,” Canon says.
Researchers filtered the air around two zoos and identified genetic material from dozens of species, a technique that could help track and conserve wildlife.
Japanese are increasingly turning to “social robots”, John Deere’s latest self-driving tractor will enable autonomous farming, a new South Australian craft beer has been designed entirely by AI.
Anhui research facility expected to provide plasma physics insights crucial to setting up industrial-size reactors to generate clean energy.
The launch tower is getting bigger.
SpaceX CEO Elon Musk has shared a video of the Starship’s impressive launch tower, ahead of a planned orbital flight.
Alquist, a house printing company, recently partnered with Habitat for Humanity to create a 3D-printed home in Williamsburg, Virginia.
I am happy to say that my recently published computational COVID-19 research has been featured in a major news article by HPCwire! I led this research as CTO of Conduit. My team utilized one of the world’s top supercomputers (Frontera) to study the mechanisms by which the coronavirus’s M proteins and E proteins facilitate budding, an understudied part of the SARS-CoV-2 life cycle. Our results may provide the foundation for new ways of designing antiviral treatments which interfere with budding. Thank you to Ryan Robinson (Conduit’s CEO) and my computational team: Ankush Singhal, Shafat M., David Hill, Jr., Tamer Elkholy, Kayode Ezike, and Ricky Williams.
Conduit, created by MIT graduate (and current CEO) Ryan Robinson, was founded in 2017. But it might not have been until a few years later, when the pandemic started, that Conduit may have found its true calling. While Conduit s commercial division is busy developing a Covid-19 test called nanoSPLASH, its nonprofit arm was granted access to one of the most powerful supercomputers in the world Frontera, at the Texas Advanced Computing Center (TACC) to model the budding process of SARS-CoV-2.
Budding, the researchers explained, is how the virus genetic material is encapsulated in a spherical envelope and the process is key to the virus ability to infect. Despite that, they say, it has hitherto been poorly understood:
The Conduit team comprised of Logan Thrasher Collins (CTO of Conduit), Tamer Elkholy, Shafat Mubin, David Hill, Ricky Williams, Kayode Ezike and Ankush Singhal sought to change that, applying for an allocation from the White House-led Covid-19 High-Performance Computing Consortium to model the budding process on a supercomputer.
Bio-Printing Complex Human Tissues & Organs — Dr. Anthony Atala, MD — Director, Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Wake Forest University.
Dr. Anthony Atala, MD, (https://school.wakehealth.edu/Faculty/A/Anthony-Atala) is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology.
A practicing surgeon and a researcher in the area of regenerative medicine, fifteen applications of technologies developed Dr. Atala’s laboratory have been used clinically. He is Editor of 25 books and 3 journals, has published over 800 journal articles, and has received over 250 national and international patents. Dr. Atala was elected to the Institute of Medicine of the National Academies of Sciences, to the National Academy of Inventors as a Charter Fellow, and to the American Institute for Medical and Biological Engineering.
Improving people’s lives globally from the world’s largest financial endowment — dr. mads krogsgaard thomsen, CEO, novo nordisk fonden, novo nordisk.
Dr. Mads Krogsgaard Thomsen, DVM, DSc., Ph.D., is the CEO of the Novo Nordisk Foundation (https://novonordiskfonden.dk/), an international foundation with a dual objective: to provide a stable basis for the commercial and research activities conducted by the companies within the Novo Group (of which Novo Nordisk A/S is the largest holdings) and to support scientific, humanitarian and social purposes. In 2020, the Novo Nordisk Foundation had a net worth of US$73.1 billion, making it the largest financial endowment in the world. Novo Nordisk Foundation owns Novo Holdings A/S, a holding company and majority shareholder of Novo Nordisk, as well as Novozymes, a global biotechnology company focused on the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The foundation is also a major shareholder in more than 75 other companies.
Originally, trained as a veterinarian / DVM at The Royal Veterinary and Agricultural University (now part of the University of Copenhagen), where he also holds a DSc. in this domain, Dr. Thomsen started his career as a PhD pharmacology student at the University of Copenhagen, after which he worked three years as a researcher at LEO Pharma. Thirty years ago, he joined Novo Nordisk, initially as Head of Growth Hormone Research and subsequently as Senior Vice President of Diabetes R&D. In 1995, he was appointed Senior Vice President of Discovery and in 2000, he became Executive Vice President of Research & Development/Chief Scientific Officer. Over the years, he has headed the development of 20 medical drugs, especially within diabetes treatment and the groundbreaking development of GLP-1 technologies.
Latest local news from Turkey, including top stories on education, minorities and more at DailySabah.com